Patents Assigned to THE GENERAL HOSPITAL CORPORATION D/B/A
-
Publication number: 20160251351Abstract: The present invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein U, J, V, X, R1a, R2b, R2c, R5 and t are as described herein. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. These compounds are useful for promoting cognitive function and enhancing learning and memory formation. In addition, these compounds are useful for treating, alleviating, and/or preventing various conditions, including for example, neurological disorders, memory and cognitive function disorders/impairments, extinction learning disorders, fungal diseases and infections, inflammatory diseases, hematological diseases, and neoplastic diseases in humans and animals.Type: ApplicationFiled: May 5, 2016Publication date: September 1, 2016Applicants: The Broad Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Massachusetts Institute of TechnologyInventors: Edward Holson, Florence Fevrier Wagner, Michel Weiwer, Li-Huei Tsai, Stephen J. Haggarty, Yan-Ling Zhang
-
Publication number: 20160177389Abstract: The invention provides novel FUS/TLS nucleic acids and proteins that comprise one or more genetic markers (for example, single nucleotide polymorphisms) and methods of use thereof including methods relating to the diagnosis of ALS or other related motor neuron disease by virtue of the presence of the mutant FUS/TLS sequence(s).Type: ApplicationFiled: August 25, 2015Publication date: June 23, 2016Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Thomas J. Kwiatkowski, JR., Robert H. Brown, JR.
-
Publication number: 20160122405Abstract: Provided herein are fusion proteins comprising a homeodomain fusion protein domain and a transcription modulator domain for treatment of various diseases or disorders such as cancer. The homeodomain fusion protein domain binds to a target gene and the transcription modulator domain either activates or represses gene transcription. The present invention also relates to polynucleotides encoding the fusion proteins, vectors comprising the polynucleotides, cells comprising the polynucleotides, vectors, or fusion proteins. Also provided are methods of use and compositions for delivery of the fusion proteins.Type: ApplicationFiled: June 6, 2014Publication date: May 5, 2016Applicants: President and Fellows of Harvard College, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Rahul Palchaudhuri, David T. Scadden, Gregory L. Verdine
-
Publication number: 20160113971Abstract: Methods and compositions are provided for treating weight related conditions and metabolic disorders by altering microbiota in a subject. One aspect provides methods and compositions to alter microbiota in a subject by administering to the subject a composition that includes a substantially purified microbiota from phyla such as Bacteroidetes, Proteobacteria, Firmicutes and Verrucomicrobia or orders such as Bacteroidales, Verrucomicrobiales, Clostridiales and Enterobacteriales or genera such as Alistipes, Clostridium, Escherichia, and Akkermansia. Another aspect includes a pharmaceutical composition for altering microbiota that includes a therapeutically effective amount of substantially purified microbiota and a pharmaceutically acceptable carrier. Yet another aspect includes methods for treating a disorder, such as obesity, in a subject in need of such treatment by changing relative abundance of microbiota in a gastrointestinal tract of the subject without or in addition to a surgical procedure.Type: ApplicationFiled: September 23, 2015Publication date: April 28, 2016Applicants: ETHICON ENDO-SURGERY, INC., The General Hospital Corporation D/B/A, Massachusetts General Hospital, President and Fellows of Harvard CollegeInventors: Lee M. Kaplan, Alice P. Liou, Peter J. Turnbaugh, Jason L. Harris
-
Publication number: 20160068885Abstract: Control agents for immunoprecipitation assays, methods of using the control agents and kits comprising the control agents are provided.Type: ApplicationFiled: September 16, 2015Publication date: March 10, 2016Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Bradley E. Bernstein, Alon Goren
-
Publication number: 20150313890Abstract: The present invention provides compounds of formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting kinase (e.g., GSK3 (e.g., GSK3? or GSK3?) or CK1) activity. The present invention further provides methods of using the compounds described herein for treating kinase-mediated disorders, such as neurological diseases, psychiatric disorders, metabolic disorders, and cancer.Type: ApplicationFiled: July 14, 2015Publication date: November 5, 2015Applicants: The Broad Institute, Inc., Dana-Farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Florence Fevrier Wagner, Jennifer Q. Pan, Sivaraman Dandapani, Andrew Germain, Edward Holson, Benito Munoz, Partha P. Nag, Michael C. Lewis, Stephen J. Haggarty, Joshua A. Bishop, Kimberly Stegmaier, Michel Weiwer, Versha Banerji
-
Publication number: 20150284356Abstract: The present invention provides compounds of Formula I, pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting fungal or parasitic growth. The compounds are useful as inhibitors of glycosylphosphatidylinositol (GPI)-anchor biosynthesis, in particular, as inhibitors of fungal Gwt1 activity. The present invention further provides methods of using the compounds described herein for treating fungal or parasitic infections. The compounds can also be used as biological probes to study the effects of inhibiting Gwt1 activity.Type: ApplicationFiled: June 21, 2013Publication date: October 8, 2015Applicants: Whatehead Institute for Biomedical Research, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Catherine McLellan, Ralph Mazitschek, Luke Whitesell, Susan L. Lindquist
-
Publication number: 20150252364Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of SMN1 or SMN2 that comprises exon 7. Methods for modulating expression of SMN1 or SMN2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of SMN1 or SMN2.Type: ApplicationFiled: May 16, 2013Publication date: September 10, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150218560Abstract: Aspects of the invention provide methods for selecting a candidate oligonucleotide for activating expression of a target gene. Further aspects of the invention provide methods of selecting a set of oligonucleotides that is enriched in oligonucleotides that activate expression of a target gene. Further aspects provide single stranded oligonucleotides that modulate gene expression and compositions and kits comprising the same. Methods for modulating gene expression using the single stranded oligonucleotides are also provided.Type: ApplicationFiled: April 20, 2015Publication date: August 6, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150218259Abstract: The invention relates to antibodies that bind cross-linked amyloid ? oligomers, and methods for using such antibodies for diagnosis and treatment of Alzheimer's disease.Type: ApplicationFiled: August 6, 2014Publication date: August 6, 2015Applicant: The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Robert Moir, Rudolph E. Tanzi
-
Publication number: 20150191427Abstract: The present invention relates to compounds of formula (I) or a pharmaceutically acceptable salt, hydrate, solvate, or prodrug thereof, wherein X1, X2, X3, X4, X5, W1, W2, W3, and W4 are as described. The present invention relates generally to inhibitors of histone deacetylase and to methods of making and using them. In one aspect, the invention relates to selective HDAC3 inhibitors useful for protecting ?-cells and improving insulin resistance. The selective HDAC3 inhibitors are also useful for promoting cognitive function and enhancing learning and memory formation.Type: ApplicationFiled: July 29, 2013Publication date: July 9, 2015Applicants: The General Hospital Corporation d/b/a Massachusetts General Hospital, The Broad Institute, Inc.Inventors: Edward Holson, Florence Fevrier Wagner, Stephen J. Haggarty, Yan-Ling Zhang, Morten Lundh, Bridget Wagner, Michael C. Lewis
-
Publication number: 20150191417Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically acceptable salts, tautomers, stereoisomers, solvates, hydrates, polymorphs, and compositions thereof. Also provided are methods and kits involving the inventive compounds for treating proliferative diseases (e.g., cancers (e.g., breast cancer, prostate cancer, lung cancer, and ovarian cancer), benign neoplasms, angiogenesis, inflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound of the invention may enhance the anti-tumor immune response by inhibiting or eliminating the immune suppression mediated by immune suppressor myeloid cells (MDSCs), inducing apoptosis, and/or inhibit or down-regulate proteins (e.g., epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 2 (HER2), estrogen receptor (ER), X-linked inhibitor of apoptosis protein (XIAP), and heat shock protein 90 (Hsp90)) in the subject.Type: ApplicationFiled: July 10, 2013Publication date: July 9, 2015Applicants: Dana-farber Cancer Institute, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Kenneth C. Anderson, Teru Hideshima, Ralph Mazitschek, Gullu Gorgun
-
Publication number: 20150191722Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of APOA1 or ABCA1. Methods for modulating expression of APOA1 or ABCA1 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of APOA1 or ABCA1.Type: ApplicationFiled: May 16, 2013Publication date: July 9, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150190411Abstract: The invention provides methods and compounds for the treatment of neurological disorders, including Alzheimer's disease, Parkinson's disease, Huntington's disease, ALS (Amyotrophic Lateral Sclerosis), traumatic brain injury, ischemic brain injury or a stroke. In one aspect the compounds are HDAC1 activators. Exemplary HDAC1 activators include metal chelators, iron chelators, deferoxamin, flavonoids, compounds comprising a catechol moity, ginkgetin K, Chembridge 5104434, sciadopilysin, tetrahydrogamboic acid, TAM-11, LY 235959, CGS 19755, SK&F 97541, etidronic acid, levonordefrin, methyldopa, ampicillin trihydrate, D-aspartic acid, gamma-D-glutamylaminomethylsulfonic acid, phenazopyridine to hydrochloride, oxalamine citrate salt, podophyllotoxin, SK&F 97541, (+?)-4-amino-3-(5-chloro-2-thienyl)-butanoic acid, (RS)-(tetrazol-5-yl) glycine, R(+)-SKF-81297, gambogic acid, and derivatives thereof.Type: ApplicationFiled: August 12, 2014Publication date: July 9, 2015Applicants: Massachusetts Institute of Technology, The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Li-Huei Tsai, Stephen J. Haggarty, Dohoon Kim
-
Publication number: 20150174138Abstract: The invention relates to methods of treatment and diagnosis of subjects with cancer. In some aspects, the invention relates to methods of treatment and diagnosis of subjects with cancer, wherein the cancer is characterized by a Notch pathway activation mutation or by resistance to a Notch pathway inhibitor.Type: ApplicationFiled: June 19, 2013Publication date: June 25, 2015Applicants: The Broad Institute, Inc., The Brigham and Women's Hospital, Inc., The General Hospital Corporation d/b/a Massachusetts General Hospital, Dana-Farber Cancer Institute, Inc.Inventors: Bradley E. Bernstein, Jon C. Aster, James E. Bradner, Birgit Knoechel, Christopher J. Ott, David Root
-
Publication number: 20150159161Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of PTEN. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of PTEN. Methods for modulating expression of PTEN using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of PTEN.Type: ApplicationFiled: May 16, 2013Publication date: June 11, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150159160Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of ATP2A2. Methods for modulating expression of ATP2A2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of ATP2A2.Type: ApplicationFiled: May 16, 2013Publication date: June 11, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150152410Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of MECP2. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of MECP2. Methods for modulating expression of MECP2 using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of MECP2.Type: ApplicationFiled: May 16, 2013Publication date: June 4, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150141320Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of a target gene. Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of a target gene. Methods for modulating expression of a target gene using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of a target gene.Type: ApplicationFiled: May 16, 2013Publication date: May 21, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee
-
Publication number: 20150133528Abstract: Aspects of the invention provide single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes (HBB, HBD, HBE1, HBG1 or HBG2). Further aspects provide compositions and kits comprising single stranded oligonucleotides for activating or enhancing expression of hemoglobin genes. Methods for modulating expression of hemoglobin genes using the single stranded oligonucleotides are also provided. Further aspects of the invention provide methods for selecting a candidate oligonucleotide for activating or enhancing expression of hemoglobin genes.Type: ApplicationFiled: May 16, 2013Publication date: May 14, 2015Applicants: RaNA Therapeutics, Inc., The General Hospital Corporation d/b/a Massachusetts General HospitalInventors: Arthur M. Krieg, Romesh Subramanian, James McSwiggen, Jeannie T. Lee